Company ContraVir Pharmaceuticals Inc Nasdaq
Equities
US21234W2026
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/16/01 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/19/03 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 03/19/03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/13/15 |
Timothy Block
BRD | Director/Board Member | 69 | 26/13/26 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/22/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,688 | 0 | 0 | 99.69 % |
Stock B | 1 | 5,472,451 | 5,455,670 ( 99.69 %) | 0 | |
Stock C | 0 | 85,581 | 0 | 0 |
Company contact information
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-14.15% | 21.84B | |
-1.05% | 21.96B | |
-5.29% | 19.21B | |
-38.29% | 17.71B | |
-4.16% | 18.08B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |